BTG Plc operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BTG Plc with three other
pharmaceutical manufacturers in Europe:
Dechra Pharmaceuticals PLC
sales of £407.10 million [US$535.66 million]
of which 64%
was European Pharmaceuticals),
Dottikon ES Holding AG
(158.23 million Swiss Francs [US$159.51 million]
of which 91%
was Pharma Products), and
(£233.20 million [US$306.84 million]
of which 100%
was Antibodies & Related Products).
BTG Plc reported sales of £620.50 million (US$816.45 million)
March of 2018.
increase of 8.8%
versus 2017, when the company's sales were £570.50 million.
Sales at BTG Plc have increased during each of the previous five years
(and since 2013, sales have increased a total of 166%).
Sales of Interventional Medicine saw an increase
12.3% in 2018, from
£216.20 million to £242.90 million.